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LONG-TERM FOLLOW-UP OF PATIENTS WHO RECEIVED EBV-SPECIFIC
CTLS FOR THE PREVENTION OR TREATMENT OF EBV-ASSOCIATED
LYMPHOPROLIFERATIVE DISEASE
Bollard, C.M.1; Onishi, H.1; Huls, M.1; Rochester, R.J.2; Benaim, E.2;
Krance, R.A.1; Brenner, M.K.1; Rooney, C.M.1; Heslop, H.E.1 1. Baylor
College of Medicine, Houston, TX; 2. St Jude Children’s Research Hos-
pital, Memphis, TN
The risk of EBV-associated Lymphoproliferative Disease
(EBV-LPD) ranges from 5-25% after T-cell-depleted BMT
from an unrelated or a mismatched-related donor. From 1993-
99, we generated donor-derived EBV-specific CTLs and
administered them as prophylaxis and treatment for this com-
plication. 59 patients received a T-cell-depleted BMT from a
matched unrelated or a haploidentical family donor. 56 patients
received CTLs prophylactically. The 4 year overall survival is
71%. 13 patients died of relapse of their primary disease and 3
of infection. Only 2 patients developed exacerbations of pre-
existing GVHD within 1 month post infusion. 9 of the patients
on the prophylaxis study had evidence of incipient EBV-LPD
prior to CTL infusion. In 6 patients the abnormalities resolved
without sequelae after CTL infusion. The other 3 developed
local inflammation during a therapeutic response with one
developing adenoid enlargement with necrosis, one developing
fever and a LLL pulmonary infiltrate and the third, a transient
elevation in transaminases. None of the 56 patients in the pro-
phylaxis study developed EBV-LPD compared to an incidence
of 11.5% in patients not receiving prophylaxis. 4 patients not
enrolled on the prophylaxis study received CTLs as treatment
for EBV-LPD. One patient with a mutation in EBNA 3b was
resistant to CTL therapy and 2 patients attained remission
after CTL therapy. The CTLs of the first 26 patients were
marked with the neo gene to track their persistence. Real time
PCR assay showed the marker gene persisted for up to 78
months in peripheral blood. Multiple integration sites were
demonstrated on inverse PCR studies confirming the persist-
ence of multiple clones. Polyclonal donor-derived EBV-specific
T-cell lines can be used safely to prevent EBV-LPD post allo-
BMT with long-term persistence of adoptively transferred
cells. However infusion of CTLs to patients with active or
incipient disease may produce morbidity secondary to tissue
inflammation at sites of disease.
REAL-TIME IN VIVO IMAGING OF EXPANDED CD8+ NK-T CELLS
INFILTRATING AND ERADICATING LYMPHOMAS
Edinger, M.; Cao, Y.; Verneris, M.R.; Bachmann, M.H.; Contag,
C.H.; Negrin, R.S. Stanford Medical School, Stanford, CA
Revealing the mechanisms of neoplastic disease and enhancing
our ability to intervene in these processes requires an increased
understanding of cellular and molecular changes as they occur in
living animals. Since light is transmitted through mammalian tis-
sues, cells expressing the bioluminescent reporter gene luciferase
can be detected within living mice using low light imaging cam-
eras. To establish animal models of leukemia and lymphoma, the B
cell lymphoma lines A20 and BCL1 were labeled with a luciferase
reporter gene. Tumor engraftment was visualized after sc, ip and iv
injections. As few as 7000 cells were detected after iv injection.
Measuring light emission over time enabled us to quantify tumor
growth within internal organs. Following iv injection of 104 A20-
luc cells in a syngeneic BMT model, tumor inﬁltration in the BM
of femurs, humeri, sternum and vertebrae was observed. Using
these tumor models we investigated the therapeutic application of a
cytotoxic cell population, previously described as cytokine induced
killer cells (CIK). These cells co-express T cell and NK cell mark-
ers and are generated from splenocytes by stimulation with IFN-γ
on day 0, followed by anti-CD3-Ab and IL-2 stimulation and
expansion over 2-3 wks. Treatment of A20-luc tumor bearing ani-
mals with CIK cells led either to a complete eradication or signiﬁ-
cant attenuation of tumor signal from sc growing tumors. To
examine trafﬁcking of these effector cells in vivo we used a retrovi-
ral transduction system to label the cells with a gfp/luciferase
fusion protein. Shortly after iv injection transduced cells were
detectable in the lungs, 16h later they were located in liver and
spleen and inﬁltrated a sc growing A20 tumor after 72h. They were
detectable at this tumor site for the following 9 days until the
tumor was finally eradicated. Using this system, unique insights
into dynamic biologcal processes can be readily visualized.
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